Emerging data on immunotherapies and tyrosine kinase inhibitors in lung cancer: 2022 ESMO Florida

Changing course and improving dismal outcomes in lung cancer: 2022 ESMO FloridaПодробнее

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

Noemi Reguart, ESMO 2019 - EGFR tyrosine kinase inhibitors in NSCLCПодробнее

Immuno-oncology agents plus tyrosine kinase inhibitors?Подробнее

A need for continued research with immunotherapy in small cell lung cancer: 2022 ESMO FloridaПодробнее

Pembrolizumab or EGFR tyrosine kinase inhibitors in NSCLC?Подробнее

Researcher comment: Positive OS data for osimertinib in FLAURA trial | Suresh RamalingamПодробнее

Opportunities for potential cure in non-metastatic non-small cell lung cancer: 2022 ESMO FloridaПодробнее

Jarrod Longcor: ESMO highlightsПодробнее

Real-world outcomes of IO & TKIs in mRCCПодробнее

ESMO Lung SymposiumПодробнее

Exploring neoadjuvant EGFR-TKIs in lung cancerПодробнее

NSCLC trial updates at ESMO 2022: ADAURA, DESTINY-Lung02, KN189, KN407 & POSEIDONПодробнее

Lung cancer highlights from ESMO 2022Подробнее

FLAURA study: a new standard of care for patients with EGFR mutated NSCLCПодробнее

Frontline Chemo and TKI Combination in EGFR+ NSCLCПодробнее

Selecting EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Lung CancerПодробнее

Novel approaches in NSCLCПодробнее

Emerging treatment strategies in EGFR-mutant NSCLC: osimertinib combinations and beyondПодробнее